CHMP recommends AZ's Komboglyze for combo treatments in Type II diabetes

EMA’s CHMP recommended expanding the label for Type II diabetes drug Komboglyze saxagliptin/metformin from AstraZeneca plc (LSE:AZN; NYSE:AZN) to include combination treatment with other products for diabetes, including insulin, in patients inadequately controlled on metformin and those products...